DGAP-News

Formycon AG: Global strategic partners bioeq and Formycon initiate pivotal phase III clinical trial with their Lucentis(R) biosimilar - Seite 2

"Intraocular anti-VEGF agents are a cornerstone in the treatment of age
related macular degeneration and other eye diseases. A high quality and
clinically proven biosimilar version of Lucentis(R) could play an important
role in broadening the access to these essential medicines and generating
much needed savings" said Professor Dr. O. Findl, Chair of the Department
of Ophthalmology at Hanusch Hospital, Vienna.

"The costs associated with the treatment of eye diseases have become a
tremendous emerging challenge for global health care systems. I am
confident that, together with our partner Formycon, we can build a strong
global presence in ophthalmology. Biosimilars like FYB201 will address the
need for affordable access to essential high-quality treatments for payors,
prescribers and patients. We continue to expand our biosimilar portfolio in
ophthalmology but also in other indications" said Nicola Mikulcik, CEO of
bioeq GmbH.

About Formycon:
Formycon is a leading independent pure play developer of biosimilars and
has become a recognized innovator in this field. The company has extensive
experience in the development of complex biological molecules. Formycon's
specialist expertise allows the company to develop high-quality biosimilars
that meet the strict regulatory requirements of highly regulated markets
such as Europe and the United States. Formycon currently has three
biosimilars under development, with further product candidates already
identified. Two biosimilar candidates have been licensed out to Santo
Holding GmbH.

About bioeq:
bioeq GmbH was established in May 2014 and is funded by the Strüngmann
Group (Santo Holding) and by Polpharma, a leading Polish pharmaceutical
company. bioeq is active in the development of biosimilars in compliance
with standards required for approval and distribution in the EU, US and
other highly regulated markets.
Starting from early stage development projects licensed from
internationally renowned partners or cell lines stemming from affiliated
companies, bioeq conducts development programs up to clinical development
and registration. bioeq's pipeline comprises several of the so-called
"third wave" biosimilars, for which patent protection is due to expire
within the next decade.
bioeq's management team combines expert scientists and senior management
with a skill set spanning from early stage development through to
commercialization of complex molecules and biosimilars.

About biosimilars:
Since their introduction in the 1980s, biopharmaceuticals have
revolutionized the treatment of serious diseases such as cancer, diabetes,